Member Info for MALTBY2002

Some good views on the impact of the data. There are 2 potential audiences for this: BP who don’t need any PR because they are likely to be already aware of AVA6K and it’s potential but will be scrutinising the data for flesh on the bones and maybe derisking before a potential investment; secondly the wider investment community including retail and it is here that the PR following the data particularly referencing the case studies will become important. Not long to wait before we find out

The term broken record would be completely wasted on LDA

Whilst we are all looking forward to the publication of the data it is the case studies that will grab the headlines

Not aware of any other information.

You are quite right this relates specifically to the 1a data release which is a QA issue rather than a regulatory issue

Yes it was mentioned to the reps of the Telegram group who met AS last week that P1a was presently going through the QA procedures but he was committed to communicating the data as planned in Q4

The data is presently with the relevant regulatory authority so the timing of the announcement will not entirely be in Al’s control. How the data will be announced obviously will be

Very true far too many people on here more interested in making childish comments not least against other bulletin boards which, with some very valuable exceptions here, provide more reasoned discussions and quality research

Many thanks for your advice. As I said your choice

You don’t have to feel represented to hear Al and Fiona clarifying further some of the complex science behind the progress the company has made to date. Your choice

Ophidian is not a member of that group so no sermon

They are representing over 15% of the shareholders many of whom like me also frequent this BB. There will obviously be no new information but a clarification of that which is already in the public domain. I like many others await their summary of this meeting which will be vetted by the Nomad with interest

Yes that’s a fair enough explanation from a trading point of view but it does not account for the fact that a significant number of traders ultimately lose money. Traders create liquidity but the biggest gains are made from investors who identify a growth stock and average down with the fluctuations

Looks like 5 patients presently being dosed in DE7. Quick turn around there

Avacta will be bought out well before 2026

Better than expected cash position, groundbreaking technology that will create a paradigm shift in chemo treatment, pipeline of further drugs looking strong with more details soon, growing diagnostic programme and marketing opportunities, all looking very positive for anyone with half a brain

I had a similar reaction when I sent this week’s news to a pal of mine who was a previous CEO in a Plc and has been an investor in the stock market since the 80’s. He went straight to the Financials and Broker notes and said he would invest only a small sum because it was high risk. Like HL’s frequent E mails to me he was horrified at my high exposure. Never been more confident

Worth listening to and for once a very fair assessment of yesterday’s developments from a financial commentator

Great interview emphasising non dilutive funding being aimed for and reduced costs with the shorter timeframe.

No p1b